Biophytis

Name

Biophytis

Legal name

BIOPHYTIS SA

Website

https://biophytis.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Longevity therapeutics / age-related disease biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Age-related therapeutics
• Sarcopenia drug development
• Longevity biotechnology
• Mas receptor activators
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Licensing and Royalties: Biophytis generates revenue through licensing agreements for its drug candidates across different territories. Examples include licensing BIO101 to Blanver for Latin America (deal valued at up to €108 million) and entering exclusive negotiations with a Chinese pharmaceutical company to license BIO101.
2. Government and Public Funding: The company secures non-dilutive funding from government sources for clinical development, including €980,000 DeepTech funding from BPI France for BIO201 in dry AMD and public funding from EMBRAPII in Brazil for obesity Phase 2 trials.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Biophytis is a clinical-stage biotechnology company developing BIO101 (20-hydroxyecdysone, branded Sarconeos/Ruvembri), a Mas receptor activator drug candidate being advanced for sarcopenia, obesity-related muscle wasting, and severe COVID-19. The company complements its pipeline with an AI-driven computational longevity platform, developed in partnership with LynxKite, for accelerated discovery of next-generation longevity therapeutics.

Product overview

Biophytis is a clinical-stage biotechnology company pioneering transformative therapies targeting longevity. The company's lead product is BIO101 (also known as Sarconeos or Ruvembri), a 20-hydroxyecdysone drug candidate developed across three indications: sarcopenia, severe COVID-19, and obesity. BIO101 functions as a Mas receptor activator. The technology portfolio includes a computational longevity platform developed in partnership with LynxKite, which uses AI-driven methods for drug discovery beyond the initial MASSIVE sarcopenia project to now also target dry age-related macular degeneration.

Differentiator

Problem solved

Functional benefit

Brands

• Sarconeos: Brand name for BIO101 drug candidate developed for severe forms of COVID-19, sarcopenia, and Duchenne muscular dystrophy
• Ruvembri
• BIO101 (20-hydroxyecdysone)
• MASSIVE

Products and services

• BIO101 (Sarconeos / Ruvembri) BIO101 (20-hydroxyecdysone), branded Sarconeos or Ruvembri, is Biophytis' lead clinical-stage drug candidate and a Mas receptor activator. It is being developed for three indications: sarcopenia (age-related muscle degeneration), obesity-related muscle wasting, and severe forms of COVID-19. The molecule targets age-related degenerative processes and aims to deliver clinically meaningful functional improvements such as 400-meter walk test performance in sarcopenia patients and respiratory function restoration in severe COVID-19 patients. It is supplied to patients through clinical trials and early access programs operated via regional pharmaceutical partners.
• Computational Longevity Platform

Quantifiable outcome

• Clinically meaningful improvement in 400-meter walk test (400MWT) at highest dose (350mg b.i.d.) in Phase 2 SARA-INT sarcopenia study
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, strategic and regional.

• Ronghui Renhe Life TechnologycoreStrategic or Co-development Partner · 2 June 2026Joint venture partner for creation of Biophytis Biopharmaceutical Holding Ltd in Hong Kong. Ronghui Renhe Life Technology is a leading Chinese conglomerate specializing in manufacturing and distribution of healthcare products. The joint venture secured $20M investment from consortium of Asian investors for Phase 3 sarcopenia trial launch.
• NebiusstrategicTechnology or Integration · 16 March 2026Cloud computing infrastructure partner providing full stack AI cloud for computational drug discovery. Nebius powers the AI-driven computational approaches developed with LynxKite for modeling biological targets and accelerating discovery of therapeutic candidates targeting age-related diseases.
• LynxKite TechnologiescoreStrategic or Co-development Partner · 12 March 2026Expanded strategic partnership for AI-driven drug discovery beyond the MASSIVE project. The collaboration combines Biophytis' expertise in age-related diseases with LynxKite's AI platform, graph analytics, and GPU computation capabilities. The partnership aims to develop Mas receptor activator drug candidates for sarcopenia and extend to dry age-related macular degeneration. Supported by Singapore's Enterprise Singapore and aligned with Singapore's RIE 2030 plan. The collaboration leverages Nebius for cloud computing infrastructure and NVIDIA GPU technologies.
• AskHelpUstrategicStrategic or Co-development Partner · 21 January 2025Co-development agreement for rare neuromuscular diseases in China. AskHelpU is the largest association in China for those affected by ALS (amyotrophic lateral sclerosis). Partnership explores potential of Sarconeos (Ruvembri) in treatment of viral respiratory failure and rare neuromuscular conditions.
• BlanvercoreChannel Partner/ Reseller/ Distributor · 20 June 2024Exclusive licensing agreement granting Blanver rights to BIO101 in Latin America. Deal valued at up to €108 million including upfront and milestone payments. Represents major territorial licensing partnership for regional commercialization.
• University of LiègestrategicStrategic or Co-development Partner · 4 December 2023Research collaboration exploring potential of Sarconeos (Ruvembri) in treatment of viral respiratory failure. Partnership leverages university's research capabilities in respiratory medicine and infectious diseases.
• Innovation Solutions PharmaregionalChannel Partner/ Reseller/ Distributor · 30 October 2023Partnership to accelerate market access for Sarconeos (BIO101) in Brazil. Innovation Solutions Pharma represents Biophytis before ANVISA to lift suspension of Early Access Program and enable treatment of up to 80 critical COVID-19 patients under mechanical ventilation in Brazilian hospital ICUs.
• SkyepharmacoreStrategic or Co-development Partner · 25 September 2023Partnership agreement for production of regulatory batches of Sarconeos (BIO101) for severe forms of COVID-19, with view to marketing authorization submissions. Skyepharma develops finished product batches meeting GMP standards required for market access filings. The company has approvals from FDA, EMA, and ANVISA enabling global commercialization.
• SEQENScoreStrategic or Co-development Partner · 18 July 2023Master agreement for production of active compound in Sarconeos (BIO101). SEQENS produces the active ingredient at its Villeneuve La Garenne plant near Paris, a historic site modernized in 2020 with a unit for high-potential active pharmaceutical ingredients. The partnership secures production for early access programs and future market authorization applications.
• Intsel ChimoscoreChannel Partner/ Reseller/ Distributor · 2 March 2023Master service agreement making Intsel Chimos the pharmaceutical operator/exploitant, partner and distributor in France for Sarconeos (BIO101) in the early access program for treatment of severe COVID-19 forms.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• BioAge Labs: Clinical-stage biotech developing therapeutics that target the biology of aging, including muscle and metabolic health. Highly comparable to Biophytis as a longevity-focused company with sarcopenia-adjacent programs and a similar small-cap, clinical-stage profile.
• Scholar Rock: Clinical-stage biopharmaceutical company developing therapeutics targeting supracellular activation of growth factors for serious diseases, with a lead program in spinal muscular atrophy and broader neuromuscular indications. Directly comparable as a small-cap muscle-disease therapeutics developer.
• Insilico Medicine: AI-driven drug discovery company with a strong focus on aging and age-related diseases, including fibrosis and oncology. Comparable to Biophytis through its combination of AI/ML-driven discovery and longevity/aging therapeutic focus.
• Unity Biotechnology: Clinical-stage biotech developing senolytic medicines to address age-related diseases by clearing senescent cells, with programs in ophthalmology and musculoskeletal conditions. Directly comparable to Biophytis as a small-cap aging-therapeutics developer.
• Edgewise Therapeutics: Clinical-stage biotech developing small-molecule therapies for muscle disorders including Duchenne muscular dystrophy and Becker muscular dystrophy. Comparable as a small-cap muscle-disease therapeutics developer targeting age-related and genetic muscle degeneration.

Broad incumbents

• Calico Life Sciences: Alphabet-backed research organization focused on the biology of aging and developing interventions to address age-related diseases. Comparable to Biophytis in longevity therapeutic focus but operates as a deep-pocketed private research platform rather than a small public clinical-stage company.
• Biosplice (formerly Samumed): Clinical-stage biotech with multiple programs in musculoskeletal disorders (osteoarthritis, degenerative disc disease) and aging-related conditions. Comparable in targeting age-related musculoskeletal disease pathways but operates a broader pipeline and is more advanced.
• Regeneron Pharmaceuticals: Large-cap biotech with approved muscle-related biologics (e.g., in GHD and genetic muscle conditions) and active research in age-related and metabolic disease. Comparable in therapeutic category but operates at vastly greater scale with diversified commercial revenue.
• Novartis: Global pharmaceutical company with established franchises in age-related conditions including sarcopenia-adjacent indications (e.g., cachexia, frailty). Comparable as a competitor in age-related disease therapeutics, but with vastly greater commercial and R&D scale than Biophytis.

Emerging players

• Keros Therapeutics: Clinical-stage biotech developing transformative treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Comparable as a small-cap clinical-stage developer in adjacent muscle and bone disorder indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biophytis

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biophytis